CY1121563T1 - Συστημα απελευθερωσης φαρμακου για χρηση στην αντισυλληψη που περιλαμβανει πυρηνα και μια θηκη - Google Patents

Συστημα απελευθερωσης φαρμακου για χρηση στην αντισυλληψη που περιλαμβανει πυρηνα και μια θηκη

Info

Publication number
CY1121563T1
CY1121563T1 CY20191100447T CY191100447T CY1121563T1 CY 1121563 T1 CY1121563 T1 CY 1121563T1 CY 20191100447 T CY20191100447 T CY 20191100447T CY 191100447 T CY191100447 T CY 191100447T CY 1121563 T1 CY1121563 T1 CY 1121563T1
Authority
CY
Cyprus
Prior art keywords
nuclear
case
delivery system
drug delivery
contracting
Prior art date
Application number
CY20191100447T
Other languages
English (en)
Inventor
Andrew Loxley
Mark Mitchnick
Gonzalo HERNÁNDEZ HERRERO
Celestino Ronchi
Original Assignee
Chemo Research, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Research, S.L. filed Critical Chemo Research, S.L.
Publication of CY1121563T1 publication Critical patent/CY1121563T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
    • A61F6/142—Wirelike structures, e.g. loops, rings, spirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Αφορά συσκευή που περιλαμβάνει (α) πυρήνα που περιλαμβάνει πολυουρεθάνη, (β) θήκη που περιλαμβάνει συμπολυμερές αιθυλενίου οξικού βινυλεστέρα, η εν λόγω δε θήκη ουσιαστικώς ή πλήρως περιβάλλει τον εν λόγω πυρήνα και (γ) ένα ή περισσότερα δραστικά συστατικά διαλυμένα ή διεσπαρμένα στον εν λόγω πυρήνα ή/και την εν λόγω θήκη και σε μία μέθοδο για παρασκευή αυτής.
CY20191100447T 2012-02-14 2019-04-24 Συστημα απελευθερωσης φαρμακου για χρηση στην αντισυλληψη που περιλαμβανει πυρηνα και μια θηκη CY1121563T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261598642P 2012-02-14 2012-02-14
PCT/EP2013/052855 WO2013120888A2 (en) 2012-02-14 2013-02-13 Core sheath drug delivery devices

Publications (1)

Publication Number Publication Date
CY1121563T1 true CY1121563T1 (el) 2020-05-29

Family

ID=47749791

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100447T CY1121563T1 (el) 2012-02-14 2019-04-24 Συστημα απελευθερωσης φαρμακου για χρηση στην αντισυλληψη που περιλαμβανει πυρηνα και μια θηκη

Country Status (17)

Country Link
US (2) US9132081B2 (el)
EP (3) EP4212146A3 (el)
AR (1) AR089990A1 (el)
CY (1) CY1121563T1 (el)
DK (1) DK2814458T3 (el)
ES (1) ES2730208T3 (el)
HR (1) HRP20190716T1 (el)
HU (1) HUE043105T2 (el)
LT (1) LT2814458T (el)
PL (1) PL2814458T3 (el)
PT (1) PT2814458T (el)
RS (1) RS58690B1 (el)
SI (1) SI2814458T1 (el)
TR (1) TR201906738T4 (el)
TW (1) TW201332585A (el)
UY (1) UY34625A (el)
WO (1) WO2013120888A2 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015044415A1 (en) * 2013-09-30 2015-04-02 Universiteit Gent Polyurethanes as oral drug delivery platform
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
EP3079659B1 (en) 2013-12-11 2020-10-28 Merck Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
CN110022794A (zh) * 2016-10-05 2019-07-16 泰坦医药品公司 具有减少的突释的用于药物递送的可植入装置
EP3395335A1 (en) * 2017-04-24 2018-10-31 Kern Pharma, S.L. Vaginal ring for the simultaneous release of two active ingredients
CN109248139A (zh) * 2017-07-14 2019-01-22 国家卫生计生委科学技术研究所 复方左炔诺孕酮阴道环的制备方法和应用
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
AU2019275409B2 (en) 2018-05-24 2024-08-15 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
CN111971026A (zh) 2018-05-24 2020-11-20 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
JP2024536800A (ja) * 2021-09-22 2024-10-08 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー 薬剤化合物を送達するための再充填可能な埋め込み型デバイス
EP4215181A1 (en) 2022-01-21 2023-07-26 Sever Pharma Solutions An intravaginal ring
EP4215180A1 (en) 2022-01-21 2023-07-26 Sever Pharma Solutions A drug delivery system
US20240315958A1 (en) * 2023-03-23 2024-09-26 Chemo Research, S.L. Method and device for providing effective contraception

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972372A (en) * 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
CN100531800C (zh) * 2004-03-24 2009-08-26 奥尔加侬股份有限公司 基于聚乙烯乙酸乙烯酯共聚物的药物递送系统
UA94118C2 (ru) * 2006-11-20 2011-04-11 Н.В. Органон Спиральная система введения лекарства
US20100316691A2 (en) * 2007-01-19 2010-12-16 University Of Utah Research Foundation Biodegradable intravaginal medical device for delivery of therapeutics
US10258571B2 (en) 2007-02-12 2019-04-16 Particle Sciences, Inc. Delivery devices containing encapsulated and/or practice-bound active pharmaceutical ingredients
CN101977651A (zh) 2008-01-25 2011-02-16 犹他大学研究基金会 线性级释放聚合物
US20100040671A1 (en) 2008-08-12 2010-02-18 Ahmed Salah U Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof
JP5869551B2 (ja) 2010-03-16 2016-02-24 タイタン ファーマシューティカルズ インコーポレイテッド 薬物送達のための不均一な埋め込み型デバイス

Also Published As

Publication number Publication date
PT2814458T (pt) 2019-05-30
DK2814458T3 (da) 2019-05-13
US9872829B2 (en) 2018-01-23
RS58690B1 (sr) 2019-06-28
SI2814458T1 (sl) 2019-06-28
EP2814458A2 (en) 2014-12-24
TR201906738T4 (tr) 2019-05-21
UY34625A (es) 2013-09-02
WO2013120888A2 (en) 2013-08-22
US20160000706A1 (en) 2016-01-07
WO2013120888A3 (en) 2013-10-31
AR089990A1 (es) 2014-10-01
PL2814458T3 (pl) 2019-08-30
ES2730208T3 (es) 2019-11-08
EP3449909A2 (en) 2019-03-06
LT2814458T (lt) 2019-05-27
HRP20190716T1 (hr) 2019-06-14
EP4212146A2 (en) 2023-07-19
EP2814458B1 (en) 2019-04-10
EP4212146A3 (en) 2023-09-27
EP3449909A3 (en) 2019-05-29
US9132081B2 (en) 2015-09-15
TW201332585A (zh) 2013-08-16
HUE043105T2 (hu) 2019-08-28
US20130209539A1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
CY1121563T1 (el) Συστημα απελευθερωσης φαρμακου για χρηση στην αντισυλληψη που περιλαμβανει πυρηνα και μια θηκη
CL2017003005A1 (es) Métodos de diagnóstico para tratamiento con linfocitos t
CO2017001994A2 (es) Compuestos activos hacia bromodominios
BR112015009189A2 (pt) conjunto de potência para um autoinjetor e autoinjetor que contém o mesmo
BR112015032718A2 (pt) composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
CR20150326A (es) Inhibidores de autotaxina
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
BR112015008723A2 (pt) aparelho para liberar agente químico em um furo de poço, método para fornecer um agente químico e método
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
CO2017002472A2 (es) Formulación de acetato de abiraterona
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
CY1124331T1 (el) Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης
ECSP17059323A (es) Formulacion de combinacion de tesofensina y betabloqueante
CY1121852T1 (el) Μορφοποιησεις και μεθοδοι παρασκευης μορφοποιησεων για χρηση στον καθαρισμο του παχεος εντερου
CO7461127A2 (es) Código para la configuración de un dispositivo de atención al paciente
UY36150A (es) Derivados de naftiridinadiona
CY1121749T1 (el) Προφαρμακα ανταγωνιστων nmda
CL2012002858A1 (es) Combinación farmacéutica que comprende 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencilamidazol-2-il-quinolin-2-ona y al menos un inhibidor de mtor; método de tratamiento; y uso para el tratamiento y la prevención de una enfermedad proliferativa tal como cáncer de mama, tumores neuroendocrinos y linfonas, entre otras.
UY35947A (es) Compuestos antagonistas selectivos de n-metil-d-aspartato (nmda) subtipo nr2b y composiciones que los contienen
BR112017011777A2 (pt) antagonista de a2a de dosagem baixa para o tratamento de tdah e doença de parkinson
MX2016016667A (es) Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer.
BR112015024877A2 (pt) vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose
AR105142A1 (es) Métodos de tratamiento del glioblastoma multiforme con terapia de células t
WO2015149006A3 (en) Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
AR097179A1 (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y flupirtina